Lectenz Bio has been accepted to the National Institutes of Health (NIH) I-Corps program for SBIR phase I awardees. The goal of the program is to accelerate the development and commercialization of innovative technologies from companies currently funded by SBIR awards. Accepted companies are provided hands-on entrepreneurship training targeted towards customer discovery.
Lectenz Bio accepted to NIH I-Corps program
Category: Lectenz Bio News
Date: April 29, 2019
Author: lectenz® Bio
To investigate the differences between reagents used to analyze N-glycans, we benchmarked our N-GlyFind™ Core-Specific Reagent against three commonly used lectins using the same 32 N-glycan array from Gao et al. (2019), allowing for a direct comparison of structural recognition across the four carbohydrate-binding proteins.